Medherant is creating a sustainable, next-generation transdermal drug delivery patch company that creates value for patients, partners and investors. We develop new applications for patch technology that have not been possible before. The company, a spin-out from the University of Warwick, is developing TEPI Patch®, a higher-dosage drug delivery patch with a constant rate of drug release.
Medherant is developing an ibuprofen transdermal patch using its TEPI Patch technology.
Methyl Salicylate Patch
We have also had significant results testing our breakthrough TEPI Patch design with methyl salicylate.
In addition to our pain relief products, our technology also works with drugs in many other therapeutic areas.